Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial-Reference-Cited by-同舟云学术

Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial

Published:2015-10 Issue: Volume:196 Page:127-131
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Brambatti Michela,Darius Harald,Oldgren Jonas,Clemens Andreas,Noack Herbert H.,Brueckmann Martina,Yusuf Salim,Wallentin Lars,Ezekowitz Michael D.,Connolly Stuart J.,Healey Jeff S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference39 articles.

1. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study;Wolf;Stroke,1991

2. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation;Nieuwlaat;Eur. Heart J.,2005

3. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from The Italian Survey of Atrial Fibrillation Management [ISAF] Study);Zoni-Berisso;Am. J. Cardiol.,2013

4. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) Study;Huxley;Circulation,2011

5. Meta-analysis of cohort and case–control studies of type 2 diabetes mellitus and risk of atrial fibrillation;Huxley;Am. J. Cardiol.,2011

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor Xa inhibitors versus warfarin in patients with non-valvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials;Annals of Medicine & Surgery;2024-01-03

2. Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2;European Cardiology Review;2023-12-15

3. Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation;Expert Review of Cardiovascular Therapy;2023-11-02

4. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON);Journal of Diabetes and its Complications;2023-08

5. Evolución clínica de los pacientes con FA y diabetes mellitus en la pandemia de COVID-19. Registro REFADI;REC: CardioClinics;2023-07